Dr Stephen Jones - Director of US Oncology Research Inc, Texas
Despite adjuvant therapy to reduce oestrogen levels, one in five breast cancer survivors will have a recurrence. The first results from the TEAM study, one of the largest clinical trials ever conducted for invasive breast cancer, demonstrated that exemestane may be more effective in postmenopausal women than current treatment with tamoxifen. Exemestane is an agent that actually stops the body from producing oestrogen. Speaking at the 2008 San Antonio Breast Cancer Symposium.